FGFR2 mutation

News alerts, weekly reports and conference planners

Entrez ID:

2263

Related biomarkers:

FGFR2 mutation	Urothelial Cancer	FGFR2 mutation	Urothelial Cancer	erdafitinib Sensitive: A1 - Approval erdafitinib Sensitive : A1	erdafitinib Sensitive: A1 - Approval erdafitinib Sensitive : A1
FGFR2 mutation	Cholangiocarcinoma	FGFR2 mutation	Cholangiocarcinoma	KIN-3248 Sensitive: B - Late Trials KIN-3248 Sensitive : B	KIN-3248 Sensitive: B - Late Trials KIN-3248 Sensitive : B
FGFR2 mutation	Cholangiocarcinoma	FGFR2 mutation	Cholangiocarcinoma	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1
FGFR2 mutation	Gastric Cancer	FGFR2 mutation	Gastric Cancer	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1
FGFR2 mutation	Solid Tumor	FGFR2 mutation	Solid Tumor	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1
FGFR2 mutation	Bladder Cancer	FGFR2 mutation	Bladder Cancer	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1
FGFR2 mutation	Cholangiocarcinoma	FGFR2 mutation	Cholangiocarcinoma	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2
FGFR2 mutation	Cholangiocarcinoma	FGFR2 mutation	Cholangiocarcinoma	ARQ 087 Sensitive: C2 – Inclusion Criteria ARQ 087 Sensitive : C2	ARQ 087 Sensitive: C2 – Inclusion Criteria ARQ 087 Sensitive : C2
FGFR2 mutation	Cholangiocarcinoma	FGFR2 mutation	Cholangiocarcinoma	futibatinib Sensitive: C2 – Inclusion Criteria futibatinib Sensitive : C2	futibatinib Sensitive: C2 – Inclusion Criteria futibatinib Sensitive : C2
FGFR2 mutation	Cholangiocarcinoma	FGFR2 mutation	Cholangiocarcinoma	TT-00420 Sensitive: C2 – Inclusion Criteria TT-00420 Sensitive : C2	TT-00420 Sensitive: C2 – Inclusion Criteria TT-00420 Sensitive : C2
FGFR2 mutation	Solid Tumor	FGFR2 mutation	Solid Tumor	TT-00420 Sensitive: C2 – Inclusion Criteria TT-00420 Sensitive : C2	TT-00420 Sensitive: C2 – Inclusion Criteria TT-00420 Sensitive : C2
FGFR2 mutation	Non Small Cell Lung Cancer	FGFR2 mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
FGFR2 mutation	Non Small Cell Lung Cancer	FGFR2 mutation	Non Small Cell Lung Cancer	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3
FGFR2 mutation	Cholangiocarcinoma	FGFR2 mutation	Cholangiocarcinoma	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3
FGFR2 mutation	Cholangiocarcinoma	FGFR2 mutation	Cholangiocarcinoma	FGFR2 inhibitor Resistant: C3 – Early Trials FGFR2 inhibitor Resistant : C3	FGFR2 inhibitor Resistant: C3 – Early Trials FGFR2 inhibitor Resistant : C3
FGFR2 mutation	Cholangiocarcinoma	FGFR2 mutation	Cholangiocarcinoma	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3
FGFR2 mutation	Melanoma	FGFR2 mutation	Melanoma	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
FGFR2 mutation	Melanoma	FGFR2 mutation	Melanoma	CTLA4 inhibitor Sensitive: C3 – Early Trials CTLA4 inhibitor Sensitive : C3	CTLA4 inhibitor Sensitive: C3 – Early Trials CTLA4 inhibitor Sensitive : C3
FGFR2 mutation	Melanoma	FGFR2 mutation	Melanoma	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
FGFR2 mutation	Urothelial Cancer	FGFR2 mutation	Urothelial Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
FGFR2 mutation	Solid Tumor	FGFR2 mutation	Solid Tumor	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3
FGFR2 mutation	Solid Tumor	FGFR2 mutation	Solid Tumor	CPL304110 Sensitive: D – Preclinical CPL304110 Sensitive : D	CPL304110 Sensitive: D – Preclinical CPL304110 Sensitive : D
FGFR2 mutation	Multiple Myeloma	FGFR2 mutation	Multiple Myeloma	infigratinib Sensitive: D – Preclinical infigratinib Sensitive : D	infigratinib Sensitive: D – Preclinical infigratinib Sensitive : D
FGFR2 mutation	Endometrial Cancer	FGFR2 mutation	Endometrial Cancer	infigratinib Sensitive: D – Preclinical infigratinib Sensitive : D	infigratinib Sensitive: D – Preclinical infigratinib Sensitive : D
FGFR2 mutation	Endometrial Cancer	FGFR2 mutation	Endometrial Cancer	PD173074 Sensitive: D – Preclinical PD173074 Sensitive : D	PD173074 Sensitive: D – Preclinical PD173074 Sensitive : D
FGFR2 mutation	Endometrial Cancer	FGFR2 mutation	Endometrial Cancer	TKI258 Sensitive: D – Preclinical TKI258 Sensitive : D	TKI258 Sensitive: D – Preclinical TKI258 Sensitive : D
FGFR2 mutation	Estrogen Receptor Positive Breast Cancer	FGFR2 mutation	Estrogen Receptor Positive Breast Cancer	fulvestrant Resistant: D – Preclinical fulvestrant Resistant : D	fulvestrant Resistant: D – Preclinical fulvestrant Resistant : D
FGFR2 mutation	Estrogen Receptor Positive Breast Cancer	FGFR2 mutation	Estrogen Receptor Positive Breast Cancer	palbociclib Resistant: D – Preclinical palbociclib Resistant : D	palbociclib Resistant: D – Preclinical palbociclib Resistant : D
FGFR2 mutation	Solid Tumor	FGFR2 mutation	Solid Tumor	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D	eFT226 Sensitive: D – Preclinical eFT226 Sensitive : D
FGFR2 mutation	Gastric Cancer	FGFR2 mutation	Gastric Cancer	KIN-3248 Sensitive: D – Preclinical KIN-3248 Sensitive : D	KIN-3248 Sensitive: D – Preclinical KIN-3248 Sensitive : D

FGFR2 mutation

Associations